EMA Gives Advice On Biomarker That Could Speed Up AML Drug Development

Traditional Clinical Endpoint Of Survival Has Made Acute Myeloid Leukemia Trials Lengthy

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".